Loading
Showed that very low-dose nivolumab added to cheap chemotherapy improves survival in head and neck cancer, a landmark for affordable immunotherapy.
Vijay Patil is Professor of Medical Oncology at Tata Memorial Hospital, part of the Tata Memorial Centre in Mumbai, specialising in head and neck oncology. He led the randomised trial of low-dose nivolumab added to triple metronomic chemotherapy in advanced head and neck cancer, which showed that very low-dose immunotherapy combined with cheap chemotherapy improves outcomes at a fraction of the cost of standard dosing, a landmark for affordable immunotherapy. His publications include the randomised study of low-dose immunotherapy in head and neck cancer. His interests are low-dose immunotherapy, metronomic chemotherapy and pragmatic trials.
| Title | Journal | Year |
|---|---|---|
| Low-dose immunotherapy in head and neck cancer: a randomized study | Journal of Clinical Oncology | 2023 |
Shares Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial), Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live, Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial), Advanced Centre for Treatment, Research and Education in Cancer.
Shares Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial), Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial), Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial), Tata Memorial Centre.
Shares Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Head and neck squamous cell carcinoma.
Shares Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial), Advanced Centre for Treatment, Research and Education in Cancer, Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial), Tata Memorial Centre.
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma.
Shares Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial), Tata Memorial Centre, Head and neck squamous cell carcinoma.
Shares Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre.
Shares Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live, Immune checkpoint inhibitors.